NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability to infinitely expand natural killer cells while significantly enhancing cytotoxicity.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 17, 2019 | Seed | $11M | 1 | — | — | Detail |